Gregory A. Otterson

Gregory A. Otterson's research centers on lung cancer, particularly non-small cell lung cancer (NSCLC), with a focus on evaluating new drug therapies, immune checkpoint inhibitors (drugs that help the immune system attack tumors), and targeted treatments for tumors with specific genetic mutations. Much of the work involves clinical trials testing new drug combinations, biomarkers that predict how patients respond to treatment, and side effects such as immune-related complications and disease spread to the brain. This work is largely clinical and translational, aiming to improve treatment strategies for patients with advanced lung cancer.

Publication output has fluctuated over the past decade, with a notable spike in 2023 followed by a decline in 2024-2025, though the underlying data suggest continued active clinical research.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026